A newly uncovered mechanism thought to be a weakness of prostate cancer cells could inspire a new and improved targeted treatment for the disease. International research led by Flinders University in Australia and South China University of Technology revealed that two enzymes called PDIA1 and PDIA5 play a crucial role in helping prostate cancer cells grow, survive and resist treatment. The enzymes act as “molecular bodyguards” for a prostate cancer-fueling protein called the androgen receptor (